<DOC>
	<DOCNO>NCT01320410</DOCNO>
	<brief_summary>The study comprise two dose period two different cohort healthy volunteer . The investigator begin single dosage period I ( 1 injection 25 mg Risperidone subject ) ; single dosage period II , different previous one ( 1 injection 37.5 mg Risperidone subject ) , second group healthy volunteer different first group start preliminary analysis make safety data plasma concentration data know formulation prolong release Risperidone use ISM® technology .</brief_summary>
	<brief_title>Pharmacokinetics , Safety , Tolerance Study Single Dose Administration Risperidone ISM®</brief_title>
	<detailed_description />
	<mesh_term>Risperidone</mesh_term>
	<criteria>1 . Healthy volunteer sex minimum age 18 year maximum age 50 year . 2 . Healthy female volunteer negative pregnancy test , childbearing age , use least 2 medically accept contraceptive method . 3 . Each volunteer must capable understanding enough complete test exams require protocol . 4 . Each volunteer must understand nature study sign inform consent document . 5 . Vital sign ( systolic diastolic blood pressure , heart rate , temperature ) ECG record within normal range . 6 . The result laboratory test ( complete blood count biochemistry ) ECG fall within normal reference range show minor deviation investigator consider clinically relevant . 7 . The investigator must consider volunteer suitable candidate prolong release intramuscular administration . 8 . Healthy volunteer must body mass index 19 27 kg/m2 , weigh 50 100 kg . 9 . Healthy volunteer may know cardiovascular disease , orthostatic hypotension , seizure , family history prolong QT interval , bradycardia , electrolyte disturbance ( hypokalemia , hypomagnesemia ) , hyperprolactinemia . 1 . Pregnant woman , nurse woman , female volunteer use effective contraceptive method . 2 . Previous history alcohol , drug , substance abuse month prior selection . Average daily alcohol consumption exceed 2 unit ( 20 g/d ) . Smokers 510 cigarette per day 3 month prior start study . 3 . History allergy , idiosyncrasy , hypersensitivity severe adverse reaction medication , contraindication treatment Risperidone record data sheet drug . 4 . Positive serology hepatitis B C , HIV . 5 . History clinical evidence cardiovascular disease , respiratory , renal , hepatic , endocrine , gastrointestinal , hematological , neurological , psychiatric , chronic disease may interfere objective trial . 6 . Major consumer stimulating beverage ( &gt; 5 cup coffee , tea , cola drink , similar per day ) . 7 . Positive urine test ethanol , cannabis , cocaine , amphetamine , benzodiazepine , opiate . 8 . Baseline platelet number 100,000/mm3 serum potassium &gt; 5.5 mEq / L. 9 . Having undergone surgery past 6 month . 10 . Plasma prolactin value outside reference range ( 40 mcIU/ml 530 mcIU/ml ) . 11 . Having participate another clinical trial three month start study . 12 . Having donate blood within 4 week start study . 13 . Having take medication regularly month prior start study symptomatic medication week start study , except oral contraceptive , vitamin , herbal remedy , dietary supplement , accord Principal Investigator coworkers designate him/her , involve risk subject interfere objective study . 14 . Taking ASA and/or NSAIDs within 10 day start trial end study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>